leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...121122123124125126127128129130131...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
    Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer. () -  Sep 21, 2021 - Abstract #ASCOQC2021ASCO_QC_649;    
    Following a sentinel toxicity event the GI medical oncology group at the Norris Cotton Cancer Center adopted a shared practice of routine screening for pathogenic DPYD gene variants prior to FP chemotherapy (5-FU or capecitabine)... Routine screening for pathogenic DPYD gene variants prior to FP chemotherapy is feasible and sustainable in the U.S. DPYD genotyping coupled with chemotherapy dose reductions for DPYD variant carriers facilitates safe and timely completion of planned chemotherapy treatments.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Supportive oncology care at home intervention for patients with pancreatic cancer. () -  Sep 21, 2021 - Abstract #ASCOQC2021ASCO_QC_625;    
    These findings demonstrate the feasibility and acceptability of a Supportive Oncology Care at Home intervention. Future work will investigate the efficacy of this intervention for decreasing healthcare use and improving patient outcomes.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Racial disparities in comprehensive biomarker testing and clinical trial enrollment among patients with metastatic colorectal cancer (mCRC). () -  Sep 21, 2021 - Abstract #ASCOQC2021ASCO_QC_586;    
    The significant relationship between NGS testing and clinical trial enrollment at any time in the database did not appear to be moderated by race; however, descriptive analyses suggest that the ongoing analyses by line of therapy and considering timing of testing may better quantify these relationships. These data may not be generalizable to the entire US population as they are obtained from a single database that is limited to practices using this EHR system.
  • ||||||||||  methotrexate / Generic mfg.
    Can high-dose methotrexate be safely administered to outpatients? () -  Sep 21, 2021 - Abstract #ASCOQC2021ASCO_QC_550;    
    Leucovorin and continuous intravenous hydration were administered via ambulatory infusion pumps. Outpatient administration of HD-MTX can be administered safely and effectively as CNS prophylaxis in select patients with DLBCL.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Enrollment change, Pan tumor:  CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) -  Sep 21, 2021   
    P2,  N=800, Recruiting, 
    Outpatient administration of HD-MTX can be administered safely and effectively as CNS prophylaxis in select patients with DLBCL. N=1200 --> 800
  • ||||||||||  Avastin (bevacizumab) / Roche
    Patients with RAS-mutated metastatic colorectal carcinoma - data from the clinical routine of over 1000 patients from the Colorectal Carcinoma (TKK) tumor registry (A7) -  Sep 20, 2021 - Abstract #DGHO2021DGHO_294;    
    Guidelines recommend chemotherapy (CT; fluoropyrimidine, irinotecan, oxaliplatin) with or without anti-angiogenic agents for two treatment lines...Between 2010 and 2018, pts with (K) RAS mut mCRC were mostly treated with a doublet CT and bevacizumab (BEV) as 1 st -line therapy, with the most frequent treatment regimens being FOLFIRI + BEV (30%), FOLFOX + BEV (25%), FOLFOX (13%) and FOLFIRI (9%)...The percentage of pts receiving 3 rd -line trifluridine / tipiracil increased over time from 9% in 2016 to 38% in 2019. This analysis of the RAS mut mCRC population enrolled prospectively in the TKK database provides important insights into treatment patterns, sequential treatments, and outcome of patients with RAS mut mCRC in routine clinical practice in Germany.
  • ||||||||||  irinotecan liposomal / CSPC Pharma
    Trial completion date, Trial primary completion date, Metastases:  Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) -  Sep 19, 2021   
    P2,  N=66, Not yet recruiting, 
    This analysis of the RAS mut mCRC population enrolled prospectively in the TKK database provides important insights into treatment patterns, sequential treatments, and outcome of patients with RAS mut mCRC in routine clinical practice in Germany. Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Journal, HEOR:  The economic burden of metastatic pancreatic cancer. (Pubmed Central) -  Sep 19, 2021   
    Also, the high proportion of untreated patients is alarming as these patients may be the most expensive of all patients. There is an unmet need in these patients for effective treatments that also reduce their economic burden.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal, Immunogenic cell death:  Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. (Pubmed Central) -  Sep 19, 2021   
    It displayed toxicity similar to that observed with its use as a first-line treatment. The predictive utility of ICD-related SNPs for the efficacy of oxaliplatin-based chemotherapy was demonstrated, warranting further validation studies to be translated into personalized treatment strategies using conventional cytotoxic agents in mCRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. (Pubmed Central) -  Sep 19, 2021   
    As in vivo markers of drug sensitivity, ETS and DoR may be integrated with several patient- and tumor-related factors to wisely drive decision-making on upfront treatment duration and intensity. Sidedness and BRAF/MMR contributed the most to survival outcomes among high risk tumours and should be interpreted in the context of risk group.
  • ||||||||||  Vectibix (panitumumab) / Amgen, Takeda
    Biomarker, Clinical, Journal:  Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer. (Pubmed Central) -  Sep 19, 2021   
    This cohort study analyzed participants in the screening procedure of the PANIRINOX (Phase II Randomized Study Comparing FOLFIRINOX + Panitumumab vs FOLFOX + Panitumumab in Metastatic Colorectal Cancer Patients Stratified by RAS Status from Circulating DNA Analysis) phase 2 randomized clinical trial...This cohort study found that tumor burden differed between patients who received an mCRC diagnosis before vs after the first COVID-19 lockdown in France. The findings of this study suggest that CRC is a major area for intervention to minimize pandemic-associated delays in screening, diagnosis, and treatment.
  • ||||||||||  irinotecan / Generic mfg.
    Clinical, Journal:  Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. (Pubmed Central) -  Sep 18, 2021   
    Folinic acid, 5FU, and irinotecan (FOLFIRI) give better PFS in rectal cancer [PFS of 21.2 (95% CI: 14.9-NR) versus 12.2 (95% CI: 10.1-13.4) months for the folinic acid, 5FU, and oxaliplatin (FOLFOX) group, P=0.009] and at trend for better PFS in right side tumor [14.9 (95% CI: 8.8-20.8) versus 11.3 (95% CI: 8.4-13.2) months for the FOLFOX group...our results support that either FOLFIRI or FOLFOX regimens give similar efficacy in both left and right metastatic colic cancer. FOLFIRI and FOLFIRINOX regimens might be preferred for metastatic rectal carcinoma.
  • ||||||||||  Avastin (bevacizumab) / Roche
    [VIRTUAL] Metastatic Colonic Adenocarcinoma in a 12-Year-Old Female () -  Sep 18, 2021 - Abstract #CAP2021CAP_181;    
    She started chemotherapy protocol (FOLFOXIRI + Bevacizumab) with interval improvement in disease on abdominal/pelvis CT scan. Because of nonspecific symptoms of pediatric colorectal carcinoma, clinicians should have a high index of suspicion to avoid diagnosis at an advanced disease stage with poor prognosis and outcomes.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    New P2 trial:  Peri-operative SLOG for Localized Pancreatic Cancer (clinicaltrials.gov) -  Sep 17, 2021   
    P2,  N=40, Recruiting, 
  • ||||||||||  Clinical, Journal:  Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. (Pubmed Central) -  Sep 17, 2021   
    Although noninferiority has not been demonstrated in the overall population, the convenience, reduced toxicity, and cost of 3-month adjuvant CAPOX suggest it as a potential option for high-risk stage II colon cancer if oxaliplatin-based chemotherapy is suitable. The relative contribution of the factors used to define high-risk stage II disease needs better understanding.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Retrospective data, Journal:  Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis. (Pubmed Central) -  Sep 17, 2021   
    No correlations were observed between the dose intensity of irinotecan, oxaliplatin, 5-fluorouracil, or bevacizumab and the overall survival, progression-free survival in the first-/second-line treatment, and time to treatment failure...Initiating systemic treatment with an irinotecan-based regimen in combination with bevacizumab improved the progression-free survival in the first-line treatment and time to treatment failure. In terms of overall survival, bevacizumab treatment after the first progression is better partnered with the same regimen as that used in the induction phase.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  COLOPEC: Adjuvant HIPEC in High Risk Colon Cancer (clinicaltrials.gov) -  Sep 16, 2021   
    P3,  N=204, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022 Active, not recruiting --> Completed